Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.64 |
| ▸ | PGR | P06401 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23962476 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL20149283 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL24923581 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL23961911 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL20149346 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL24591928 | 1.00 | NR3C1 (0.64) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL26228034 | 0.94 | NR3C1 (0.65) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL21153648 | 0.93 | NR3C1 (0.73) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL21153780 | 0.93 | NR3C1 (0.73) | NR3C1PGRLMNAHIF1AAR | |
| SCHEMBL10073752 | 0.93 | NR3C1 (0.73) | NR3C1PGRLMNAHIF1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10711032-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2018089373-A9 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018089373-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | NR3C1 4351/4885PGR 2846/4885LMNA 2253/4885 |
| US-20180155389-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 444/4885LMNA 3817/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | NR3C1 565/4885PGR 3767/4885LMNA 3244/4885 |
| US-10711032-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 444/4885LMNA 3817/4885 |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 432/4885LMNA 3616/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | NR3C1 1628/4885PGR 3140/4885LMNA 2924/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | NR3C1 2/4885PGR 432/4885LMNA 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.